Chong Kun Dang Pharmaceutical Corporation

Hk Inno.n Corporation

Ha Na Yu

Soo Yeon Jung

Min Hyo Ki

Ji-Yeon Park

Hyuk Woo Lee

Seung Chan Kim

So Hyun Park

So Young Ki

Ho-Youl Lee

Jin Young Ko

Sung Won An

Dongkyu Kim

Sung Bum Jung

Won Kyu Yang

Sang Phil Yoon

Myeongjoong Kim

Ye-Lim Lee

Mi Kyung Ji

Hye Jung Baik

Ki Seong Ko

The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.

Heterocyclic compound as a protein kinase inhibitor

Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same

Growing community of inventors

Gyeonggi-do, South Korea

Ha Na Yu